|
FGF23 (RU/mL)
|
Before sodium bicarbonatea
|
After sodium bicarbonate
|
p-value
|
|---|
|
Taking vitamin Db
|
|
Yes (n = 9)
|
217.0 (146.4–353.2)*
|
327.4 (231.7–410.9)
|
0.31
|
|
No (n = 20)
|
121.2 (85.1–162.4)*
|
147.4 (107.0–196.5)
|
0.08
|
|
Taking paricalcitol
|
|
Yes (n = 3)
|
353.2 (98.9–824.9)**
|
399.1 (327.4–410.9)
|
0.59
|
|
No (n = 17)
|
146.4 (116.5–217.0)**
|
185.7 (129.9–238.4)
|
0.009
|
|
Increased paricalcitol dose
|
|
Yes (n = 1)c
|
98.8
|
399.1
|
N/A
|
|
No (n = 19)
|
155.5 (116.5–286.5)
|
186.4 (129.9–306.4)
|
0.08
|
|
Participant #16d
|
|
Yes (n = 1)
|
824.9
|
410.9
|
N/A
|
|
No (n = 19)
|
146.4 (98.8–248.3)
|
186.4 (129.9–306.4)
|
0.01
|
- FGF23 was expressed in median (interquartile range)
- Abbreviation: N/A not applicable
- *p-value comparing FGF23 between those taking vitamin D and those not taking vitamin D = 0.06
- **p-value comparing FGF23 between those taking paricalcitol and those not taking paricalcitol = 0.02
- aVariables for “before sodium bicarbonate” were the mean of values between the initial visit and after 2-week placebo
- bVitamin D used included ergocalciferol, cholecalciferol and paricalcitol
- cParticipant #3 had paricalcitol dose increased during the study
- dParticipant #16 had very a high FGF23 level at baseline
